Recombinant Epstein-Barr virus Epstein-Barr nuclear antigen 3(EBNA3),partial CSB-EP667300EFC
Specifications
| 20ug / 100ug / 1mg price = 100ug |
Alternative Name(s):
(EBNA-3)(EBV nuclear antigen 3)(Epstein-Barr nuclear antigen 3A)(EBNA-3A)(EBV nuclear antigen 3A)
Species: (Organism)
Epstein-Barr virus (strain GD1) (HHV-4) (Human herpesvirus 4)
Gene Names:
EBNA3
Tag info:
N-terminal 10xHis-tagged and C-terminal Myc-tagged
Target Protein AA Sequence:
MDKDRPGDPALDDNMEEEVPSTSVVQEQVSAGDWENVLIELSDSSSEKEAEDAQLEPAQKGTKRKRVDHDAGGSAPARPMLPPQPDLPGREAILRRFPLDLRTLLQAIGAAATRIDTRAIDQFFGSQISNTEMYIMYA
Expression Region:
1-138aa
Subcellular Location:
Tissue Specificity:
Protein Length:
Partial
Pathway:
Mol. Weight:
22.6 kDa
Purity:
Greater than 90% as determined by SDS-PAGE.
Form:
Liquid or Lyophilized powder
Buffer:
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Research Areas:
Others
Function:
Involvement in disease:
Relevance:
Plays an essential role for activation and immortalization of human B-cells. Represses transcription of viral promoters TP1 and Cp through interaction with host RBPJ, and inhibits EBNA2-mediated activation of these promoters. Since Cp is the promoter for all EBNA mRNAs, EBNA3A probably contributes to a negative autoregulatory control loop.
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Protein Families:
Reference:
"A structural basis for varied alphabeta TCR usage against an immunodominant EBV antigen restricted to a HLA-B8 molecule." Gras S., Wilmann P.G., Chen Z., Halim H., Liu Y.C., Kjer-Nielsen L., Purcell A.W., Burrows S.R., McCluskey J., Rossjohn J. J Immunol 188:311-321(2012) .
